Revelation Biosciences Reports Q2 2026 Financial Results

What Happened
Revelation Biosciences, Inc. announced its financial results for the three and six months ended June 30, 2026 and furnished a press release reporting those results on August 6, 2026. The company filed a Form 8-K (Item 2.02) to disclose the results and included the press release as Exhibit 99.1.

Key Details

• Filing date: August 6, 2026 (Form 8-K furnished to the SEC).
• Period covered: Three- and six-months ended June 30, 2026.
• Exhibit: Press release dated August 6, 2026 furnished as Exhibit 99.1.
• Signature: Filing executed by Chester S. Zygmont, III, Chief Financial Officer, on August 6, 2026.

Why It Matters
This 8-K is the company’s formal disclosure that its quarterly financial results have been released; investors should review the press release (Exhibit 99.1) for the specific revenue, earnings, cash position and other metrics that drive valuation and near-term outlook. The filing signals updated operating and financial information is available and may affect analyst estimates, stock performance, and investor decisions.